Are resistant to drug therapy often alive, re-inhabit remote metastatic sites and the site of origin, a subset of [challenges] tumor cells, causing morbidity and recurrence of detectable disease. Cancer many tumor cells having the characteristics of drug resistance change and increased metastatic potential and invasive-competent, and the conversion morphological similar to EMT conversion or morphological bring (epithelial-mesenchymal transition) EMT I considered there. Lose normal adhesion properties of epithelial cells, loss of expression of the mesenchymal marker E- and cadherin expression, increased motility, increased invasiveness, as well as cells that the EMT is a set including the increased resistance to cell death I make a change of. For example, to provide (LOXL2) binder lysyl oxidase-like 2, which comprises an antibody that specifically binds to LOXL2 polypeptides disclosed [MEANS FOR SOLVING PROBLEMS] The present application further provides a composition comprising the same. It can be used in therapeutic and diagnostic methods for various, the binder is also provided them. [Selection Figure Figure 2A【課題】 腫瘍細胞のサブセットは、しばしば薬物療法に抵抗性であり、生存して、起点の部位及び遠隔転移部位で再生息し、検出可能な疾患の再発及び罹患を引き起こす。侵襲能及び転移能の増大並びに薬物抵抗性変化の特性を有する多くの癌腫瘍細胞は、EMT(上皮間葉転換)をもたらす形態学的な転換又はEMTに類似した形態学的な転換をしていると考えられる。EMTをする細胞は、上皮細胞の正常な付着特性を失い、E-カドヘリン発現及び間葉マーカーの発現の喪失、運動性の増大、侵襲性の増大、並びに細胞死に対する抵抗性の増大を含む一連の変化をする。【解決手段】 本願の開示は、例えば、LOXL2ポリペプチドに特異的に結合する抗体を含むリシルオキシダーゼ様2(LOXL2)結合剤を提供し;さらに、これを含む組成物を提供する。前記結合剤は、各種の治療及び診断方法において使用でき、これらも提供される。【選択図】 図2A
